2. Academic Validation
  3. Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN

Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN

  • Leukemia. 2020 Apr;34(4):1197-1201. doi: 10.1038/s41375-019-0620-8.
Chad C Bjorklund 1,  Jian Kang 1,  Michael Amatangelo 1,  Ann Polonskaia 1,  Mark Katz 1,  Hsiling Chiu 1,  Suzana Couto 2,  Maria Wang 2,  Yan Ren 2,  Maria Ortiz 3,  Fadi Towfic 1,  J Erin Flynt 1,  William Pierceall 1,  Anjan Thakurta 4
Affiliations

Affiliations

  • 1 Celgene Corporation, Summit, NJ, USA.
  • 2 Celgene Corporation, San Diego, CA, USA.
  • 3 Celgene Corporation, CITRE, Sevilla, Spain.
  • 4 Celgene Corporation, Summit, NJ, USA. [email protected].
PMID: 31719682 DOI: 10.1038/s41375-019-0620-8
Figures
Products